6533b7d0fe1ef96bd125ba99
RESEARCH PRODUCT
Real life experiences in HCV management in 2018
Nicola CaporasoGiovanni Battista GaetaStefano BonoraGiovanni Di PerriFrancesca Ceccherini-silbersteinSergio BabudieriRaffaele BrunoGiuliano RizzardiniPietro LamperticoPietro AndreoneGloria TalianiAlessio AghemoTullio PrestileoNicola CoppolaAnna Linda ZignegoAntonio GasbarriniVito Di MarcoMassimo AndreoniF. CartabellottaAdriano M. PellicelliAlfredo AlbertiGiovanni RaimondoMaurizia Rossana BrunettoValeria CentoAlessia CiancioMauro ViganòSavino BrunoMassimo PuotiCarlo Federico PernoVincenza CalvarusoAntonio CraxìPiero ColombattoStefano Fagiuolisubject
0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusinessdescription
Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-15 |